A Randomized, Double-blind, Placebo-controlled Trial To Evaluate The Role Of Curcumin In Prostate Cancer Patients With Intermittent Androgen Deprivation
Notes for this study:
||(ng/ml). Median and interquartile range change. Placebo: 2.7 (1.11-3.7). Curcumin: 2.85 (1.87-4.75)
|Number of Subjects
||18-29, 30-44, 45-64, 65+
||Obese, Overweight, Average, Underweight
In a randomized, double-blind, placebo-controlled trial, 97 prostate cancer patients undergoing intermittent androgen deprivation were assigned to take 1,440 mg of a curcuminoid powder daily or placebo for 6 months at the beginning of cessation of androgen deprivation therapy.
Funding issues for this study:
The primary outcome was the duration of the period of androgen deprivation therapy cessation. Participants were put back on androgen deprivation therapy once their disease worsened sufficiently to warrant it. There was no statistically significant difference between the curcumin and placebo groups for the duration before requiring androgen deprivation therapy, and the curcumin group had a slightly shorter median relapse rate. During curcumin/placebo supplementation, the curcumin group was significantly less likely to see an increase in prostate-specific antigen of more than 2 ng/ml than the placebo group, but there was no statistically significant difference between groups in the median increase in prostate-specific antigen or testosterone levels.
There was no statistically significant difference between groups for the evaluation of prostate cancer symptoms or quality of life. However, the curcumin group had significantly fewer adverse events.
"This research was conducted with financial support provided by the OTTOGI Corporation, Anyang, Korea. The authors have stated that they have no conflicts of interest, including any financial or personal relationships with other people or organizations that could inappropriately influence their work."